Seer (SEER) Proxy filing summary

Executive summary

• Letter to shareholders highlights significant scientific progress and urges support for the board's nominees at the July 28, 2026 Annual Meeting.

• Activist shareholders Radoff and Torok submitted director nominations and acquisition proposals below the company's cash value.

• Board emphasizes a clear strategy to build the proteomics market and create long-term value.

• Forward-looking statements address ongoing innovation, financial discipline, and market expansion.

Voting matters and shareholder proposals

• Shareholders are urged to vote "FOR" the seven board-nominated directors using the BLUE proxy card.

• Three unsolicited acquisition proposals from activists are opposed by the board.

• Activist nominees are criticized for lacking relevant experience and for a short-term focus.

Board of directors and corporate governance

• Board consists of experienced members with deep scientific, investment, and governance backgrounds.

• Three directors targeted by activists have significant tenure and investment in the company.

• Board is described as independent, highly engaged, and purpose-built for the company's strategy.